Rheumatoid Arthritis and cannabis in Mississippi
The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.
- ✗ No
- LEGAL
- Up to 3.5 g cannabis-eq…
- POSSESSION
- $25/yr
- STATE FEE
- 3–14 d
- TIMELINE
Mississippi statute and program
The Mississippi Medical Cannabis Program is the operating authority for Mississippi patient certification. The authoritative legal text is: Mississippi Medical Cannabis Act: Senate Bill 2095 of 2022 (codified at Miss. Code Ann. §41-137-1 et seq.). The program portal is at Mississippi Medical Cannabis Program.
What the evidence says about cannabis and Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the body's immune system attacks the synovium (the membrane lining the joints), causing inflammation, pain, swelling, stiffness, and progressive joint damage. RA typically affects the small joints of the hands and feet symmetrically, often with morning stiffness lasting more than an hour. Untreated, RA can cause permanent joint deformity, bone erosion, and significant disability. Extra-articular manifestations include rheumatoid nodules, interstitial lung disease, vasculitis, and accelerated cardiovascular disease.
For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Rheumatoid Arthritis page.
How to qualify in Mississippi
The Mississippi Medical Cannabis Program requires the following registration steps for a Rheumatoid Arthritis patient (or any qualifying diagnosis):
- See a Mississippi-licensed practitioner registered with the MMCP. Under the Mississippi Medical Cannabis Act (SB 2095, 2022), a Mississippi-licensed physician, NP, PA, or optometrist who has completed the MSDH Medical Cannabis Program (MMCP) practitioner education course may certify a patient. Qualifying conditions under §41-137-3 include cancer, Parkinson’s, Huntington’s, MS, ALS, seizures, Crohn’s, ulcerative colitis, sickle-cell, Alzheimer’s, autism, cachexia, severe nausea, chronic and debilitating pain, PTSD, severe intractable pain, and opioid-use disorder.
- Apply through the Mississippi Medical Cannabis Program portal. The practitioner submits the written certification electronically. The patient then completes the online registration in the MMCP patient portal with a Mississippi driver license or state ID and a passport-style photo. Caregivers are registered through the same portal and pass a state and federal background check.
- Pay the $25 state registration fee. The annual Mississippi MMCP patient registry card fee is $25 (caregiver registration is also $25). Veterans, Medicaid patients, and patients with terminal illness pay a reduced fee of $15. Fees are paid online through the MMCP portal at registration.
- Receive the registry card and purchase from a Mississippi dispensary. Mississippi MMCP registry cards are typically issued within five business days of complete application. With the card, patients may purchase up to 3 Mississippi Medical Cannabis Equivalency Units per week from any of the licensed Mississippi dispensaries. Mississippi does not honor out-of-state medical cards. Cards renew annually with a fresh practitioner certification.
- State registration fee
- $25
- Physician visit (typical)
- $200–$350
- Certification to card
- 3–14 days
- Out-of-state patients
- Not eligible
- Minors
- Eligible with caregiver
For full Mississippi registration steps, fees, and reciprocity rules, see the Mississippi cannabis-laws page.
ICD-10 code
A certifying physician documenting Rheumatoid Arthritis for the Mississippi medical cannabis program will typically record ICD-10 M06.9 or SNOMED-CT 69896004 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.
Frequently asked questions
Does Mississippi list Rheumatoid Arthritis as a qualifying condition for medical cannabis?
No. Mississippi's qualifying-condition list does not currently include Rheumatoid Arthritis, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Rheumatoid Arthritis in Mississippi have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Mississippi program rules change, so verify the current list with the regulator before drawing a final conclusion.
How do I get a Mississippi medical marijuana card for Rheumatoid Arthritis?
Because Mississippi does not currently list Rheumatoid Arthritis as a qualifying condition, a card for Rheumatoid Arthritis alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Mississippi who is registered with Mississippi Medical Cannabis Program and willing to evaluate Rheumatoid Arthritis cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Mississippi does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. The authoritative source for the current process is the Mississippi Medical Cannabis Program site at https://mmcp.ms.gov/; the state updates fees, forms, and physician registration rules periodically.
What does the evidence say about cannabis for Rheumatoid Arthritis?
For Rheumatoid Arthritis, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Rheumatoid Arthritis lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Rheumatoid Arthritis should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Rheumatoid Arthritis and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Rheumatoid Arthritis; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.
Sources
- Mississippi Medical Cannabis Act: Senate Bill 2095 of 2022 (codified at Miss. Code Ann. §41-137-1 et seq.)accessed May 16, 2026
- Mississippi State Department of Health: Medical Cannabis Programaccessed May 16, 2026
- Mississippi Department of Revenue: Cannabis Equivalency Unitaccessed May 16, 2026
- Wikipedia: Cannabis in Mississippiaccessed May 16, 2026
- Miss. Code Ann. §41-29-139: Prohibited acts; penalties (controlled substances)accessed May 18, 2026
- In re Initiative Measure No. 65 v. Watson, 333 So. 3d 558 (Miss. 2021)accessed May 18, 2026
- Mississippi Legislature bill trackeraccessed May 18, 2026
- NORML: Mississippi Laws & Penaltiesaccessed May 18, 2026
- Marijuana Policy Project: Mississippiaccessed May 18, 2026
- National Academies of Sciences, Engineering, and Medicine (2017): The Health Effects of Cannabis and Cannabinoidsaccessed May 18, 2026
- American College of Rheumatology: Cannabis & Rheumatic Diseasesaccessed May 16, 2026